BRCA2 and breast cancer: A systematic review of the cost-effectiveness of healthcare programs involving genetic testing of the two major breast cancer genes, BRCA1 and BRCA2 indicated that family history-based screening programs are cost-effective (D’Andrea et al., 2016).